UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):		August 19, 2009

Altus Pharmaceuticals Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-51711	04-3573277
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

610 Lincoln Street, Waltham, Massachusetts		02451
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		781-373-6000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 19, 2009, Altus Pharmaceuticals Inc. (the "Company") submitted to the Listing Qualifications Department of the Nasdaq Stock Market ("NASDAQ") an application to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. On August 21, 2009, the Company received notice from NASDAQ that its application to transfer listing of its common stock had been approved. The transfer will be effective at the opening of the market on August 26, 2009. The Company will continue to trade under the symbol "ALTU."

The NASDAQ Capital Market is a continuous trading market that operates in the same manner as The NASDAQ Global Market. All companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ’s corporate governance standards. The Company believes it is in compliance with the minimum stockholders’ equity requirement and all other applicable criteria for continued listing on The NASDAQ Capital Market, but for the $1.00 bid price requirement. As a result of the market transfer, the Company is no longer subject to delisting from NASDAQ as a result of the previously disclosed stockholders’ equity deficiency as of June 30, 2009, but it will need to comply with The NASDAQ Capital Market’s continued listing requirements on an ongoing basis. The Company expects to have at least 180 days to meet the $1.00 bid price requirement.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Altus Pharmaceuticals Inc.

August 21, 2009	By:	Thomas J. Phair, Jr.

		Name: Thomas J. Phair, Jr.
		Title: Vice President, Finance and Treasurer

Altus Pharmaceuticals Inc. 8-K